Bicycle Therapeutics names business chief
This article was originally published in Scrip
Executive Summary
Cambridge, UK-based Bicycle Therapeutics, an emerging biotech company developing first-in-class bicyclic peptide targeted drugs, has named Arvind Hundal president and chief business officer. Dr Hundal has more than 20 years' experience in the life sciences sector, the majority of which have been in business development and strategy roles. She was most recently chief business officer and senior management team member at Zealand Pharma and was a part of the team that lead the successful initial public offering in 2010.